IFN-γ targeted to fibronectin EDA, EDB, or CD70 demonstrated superior antitumor activity, compared to non-specific IFN-γ, in distinct models: sarcoma, teratocarcinoma, and lung cancer. This evidence concerns the gene IFNG and lung cancer.